AI Predicts Heart Disease Risk Up to a Decade Early

What Happened

Researchers have found that artificial intelligence can predict a patient's risk of developing heart disease up to 10 years before clinical symptoms emerge, according to findings published and reported by The Eastleigh Voice on October 26, 2026. The study identifies sleep studies, a diagnostic tool already in widespread clinical use for sleep disorders, as a potential source of cardiovascular risk data when analysed by AI models.

What the Study Found

The research indicates that AI systems, when applied to data collected during standard sleep studies, can surface patterns linked to future heart disease. Sleep studies, formally known as polysomnography, record a range of physiological signals including brain activity, oxygen levels, heart rate, and breathing patterns over the course of a night. The study's findings suggest these signals contain information relevant to long-term cardiovascular health that conventional clinical review does not routinely extract.

The 10-year prediction window is notable. Current cardiovascular risk assessment tools, such as the Framingham Risk Score, rely on blood tests, blood pressure measurements, age, and lifestyle factors. The study points to sleep study data as an additional or alternative input that may expand the reach and accuracy of early detection efforts.

Background

Cardiovascular disease remains the leading cause of death globally, according to the World Health Organization, which estimates it accounts for approximately 17.9 million deaths per year. Early detection is a central focus of preventive cardiology, with clinical guidelines in the United States and Europe emphasising risk stratification in patients before symptoms develop.

Sleep studies are already a common clinical tool. They are primarily ordered to diagnose obstructive sleep apnea and related disorders. The infrastructure for conducting and storing sleep study data is therefore already established in hospital systems across many countries, which could reduce barriers to implementing AI-based cardiovascular screening based on this approach.

AI applications in medical imaging and diagnostics have expanded significantly in recent years. Prior studies have demonstrated AI's ability to detect conditions including diabetic retinopathy, certain cancers, and arrhythmias from electrocardiogram data. Cardiovascular risk prediction from sleep data represents an extension of this broader pattern of applying machine learning to existing clinical datasets.

What It Means in Practice

If validated at scale and adopted clinically, the approach could allow physicians to use sleep study appointments, which patients already attend for respiratory reasons, as a dual-purpose screening event for cardiovascular risk. Patients flagged as high risk could then be referred earlier for cardiology assessment, lifestyle intervention, or preventive medication.

The practical pathway from study findings to clinical use involves several steps. Results would typically need replication in larger and more diverse patient populations, review by regulatory bodies such as the U.S. Food and Drug Administration or the European Medicines Agency, and integration into clinical workflow and electronic health record systems. None of these steps were described as complete or imminent in the current reporting.

The study does not specify which AI architecture or model type was used, which organisation or research institution led the work, or the size and demographic composition of the patient cohort studied. Those details were not available in the wire report at time of publication.

What Happens Next

Further peer review, independent replication studies, and potential regulatory submissions would be required before AI-based cardiovascular risk screening from sleep data could move toward routine clinical deployment.